Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase NA × Recurrence × tislelizumab × Clear all

Phase

Phase 2 4 Phase NA 1 Phase 3 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 3 Adenocarcinoma of Lung 2 Recurrence 1 Non-Small Cell Lung Cancer Without Mutation in Epidermal Growth Factor Receptor (Disorder) 1 Neoplasms 1 Liver Neoplasms 1 Glioblastoma 1 Endometrial Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Advanced Solid Tumor 1

Interventions

Radiotherapy 10 fludarabine phosphate 6 Cyclophosphamide 6 Peripheral Blood Stem Cell Transplantation 5 Filgrastim 5 Cyclosporine 5 Whole-Body Irradiation 4 Surgical Procedures, Operative 4 Radiofrequency Ablation 4 Mycophenolic Acid 4 Melphalan 4 Drug Therapy 4 Cisplatin 4 Busulfan 4 Antilymphocyte Serum 4 Surveys and Questionnaires 3 Radiosurgery 3 Methotrexate 3 Injections 3 Cord Blood Stem Cell Transplantation 3 fludarabine 2 Vinblastine 2 Videotape Recording 2 Standard of Care 2 Procarbazine 2 Prednisolone 2 Practice Guidelines as Topic 2 Mastectomy 2 Lidocaine 2 Hepatectomy 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05277675 2022-03-14

RANT

Southwest Hospital, China

Phase NA Unknown

Gastrointestinal

Carcinoma, Hepatocellular, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡